Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation.

Chakkera HA, Chang YH, Bodner JK, Behmen S, Heilman RL, Reddy KS, Mulligan DC, Moss AA, Khamash H, Katariya N, Hewitt WR, Pitta TL, Frassetto LA.

Transplant Proc. 2013 Jan-Feb;45(1):137-41. doi: 10.1016/j.transproceed.2012.10.023.

PMID:
23375287
2.

Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.

Op den Buijsch RA, Christiaans MH, Stolk LM, de Vries JE, Cheung CY, Undre NA, van Hooff JP, van Dieijen-Visser MP, Bekers O.

Fundam Clin Pharmacol. 2007 Aug;21(4):427-35.

PMID:
17635182
3.

Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.

Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, Caccamo C, Bertani T, Palazzo U, Polidori P, Gridelli B, D'Alessandro N.

Int J Mol Med. 2011 Dec;28(6):1093-102. doi: 10.3892/ijmm.2011.794. Epub 2011 Sep 12.

PMID:
21922127
4.

Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.

Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppali E, Torresani E, Edefonti A.

Pharmacol Rep. 2010 Nov-Dec;62(6):1159-69.

5.

Pharmacokinetic differences corroborate observed low tacrolimus dosage in Native American renal transplant patients.

Grover A, Frassetto LA, Benet LZ, Chakkera HA.

Drug Metab Dispos. 2011 Nov;39(11):2017-9. doi: 10.1124/dmd.111.041350. Epub 2011 Aug 17.

6.

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH.

Clin Chem. 2011 Nov;57(11):1574-83. doi: 10.1373/clinchem.2011.165613. Epub 2011 Sep 8.

7.

Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.

Rahsaz M, Azarpira N, Nikeghbalian S, Aghdaie MH, Geramizadeh B, Moini M, Banihashemi M, Darai M, Malekpour Z, Malekhosseini SA.

Exp Clin Transplant. 2012 Feb;10(1):24-9.

8.

Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period.

Zhang X, Wang Z, Fan J, Liu G, Peng Z.

Eur J Clin Pharmacol. 2011 Aug;67(8):803-13. doi: 10.1007/s00228-011-0993-8. Epub 2011 Feb 26.

PMID:
21359536
9.

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.

Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T.

Transplantation. 2004 Oct 27;78(8):1182-7.

PMID:
15502717
10.

Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.

Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L.

Gene. 2013 Jan 10;512(2):226-31. doi: 10.1016/j.gene.2012.10.048. Epub 2012 Oct 26.

PMID:
23107770
11.

Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.

Shi XJ, Geng F, Jiao Z, Cui XY, Qiu XY, Zhong MK.

J Clin Pharm Ther. 2011 Oct;36(5):614-24. doi: 10.1111/j.1365-2710.2010.01206.x. Epub 2010 Oct 5.

PMID:
21916909
12.

CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.

Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y.

Clin Pharmacol Ther. 2007 Dec;82(6):711-25. Epub 2007 May 9.

PMID:
17495880
13.

Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.

Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, Habuchi T.

Transplant Proc. 2005 May;37(4):1730-2.

PMID:
15919447
14.

Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.

Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS.

Clin Transplant. 2005 Oct;19(5):638-43.

PMID:
16146556
15.

Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.

Cho JH, Yoon YD, Park JY, Song EJ, Choi JY, Yoon SH, Park SH, Kim YL, Kim CD.

Transplant Proc. 2012 Jan;44(1):109-14. doi: 10.1016/j.transproceed.2011.11.004.

PMID:
22310591
16.

The effect of ABCB1 C3435T polymorphism on pharmacokinetics of tacrolimus in liver transplantation: a meta-analysis.

Liu YY, Li C, Cui Z, Fu X, Zhang S, Fan LL, Ma J, Li G.

Gene. 2013 Dec 1;531(2):476-88. doi: 10.1016/j.gene.2013.09.024. Epub 2013 Sep 13.

PMID:
24042126
17.
18.

Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.

Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, Narita S, Tsuchiya N, Habuchi T, Miura M.

Transplantation. 2012 Nov 27;94(10):1013-9. doi: 10.1097/TP.0b013e31826bc400.

PMID:
23073468
19.

CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.

Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, Inui K.

Pharmacogenetics. 2004 Jul;14(7):471-8.

PMID:
15226679
20.

The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients.

Akbas SH, Bilgen T, Keser I, Tuncer M, Yucetin L, Tosun O, Gultekin M, Luleci G.

Transplant Proc. 2006 Jun;38(5):1290-2.

PMID:
16797284

Supplemental Content

Support Center